Article Text

PDF
GW24-e1167 Lvosimendan of Chronic Heart Failure Patients With Left Ventricular Systolic Function and VO2MAX
  1. Guo Zhi-yong,
  2. Teng Zhi-tao,
  3. Chen Yan,
  4. Zhao Pei-yong
  1. WeiHai Municipal Hospital Heart Center

Abstract

Objectives Lvosimendan on chronic systolic heart failure (CHF)in patients with left ventricular function and exercise tolerance.

Methods Selected 69 patients with different causes of CHF were randomly divided into two groups, control group of 32 patients were treated digitalis, diuretics, giotensin convening enzyme inhibitors and other conventional treatment and Lvosimendan of 37 patients with conventional treatment in the control group Based on the Lvosimendan (0.05 or 0.1ug·kg-1·min-1) for 24 hours. Clinical efficacy (LVEF, CEPT) were observed before and after treatment.

Results one week after treatment, Lvosimendan group Was significantly higher than the total effective rate (P < 0.05). Lvosimendan group of LVEF and VO2MAX than the control group before treatment and increased significantly (P < 0.01 and P < 0.05).

Conclusions Lvosimendan can improve left ventricular function in patients with CHF to improve exercise capacity and VO2MAX, good security.

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.